Filing Flows › Bioventus (BVS) › Q2 2025
Bioventus (BVS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Bioventus (BVS) reported revenue of $148M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +19% from the quarter before. Operating margin was 12.4%, net earnings $7.5M (5.1% of revenue).
Bioventus, Q2 2025: revenue $148M (-2% year over year), operating margin 12.4%, net earnings $7.5M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $148M | +19% | -2% |
| Gross profit | $102M | +23% | -1% |
| Operating profit | $18.4M | +277% | — |
| Net earnings | $7.5M | — | — |
| Operating cash flow | $25.9M | — | +71% |
| Free cash flow | $25.3M | — | +67% |
What changed
Revenue was $147.7M in Q2 2025, down 2% year over year and up 19% from the previous quarter.
Gross margin was 69.1%, up 0.6 points from a year earlier. Operating profit was $18.4M, a 12.4% margin (up 33.3 points year over year). Operating expenses fell 38% while revenue fell 2%. Net earnings were $7.5M. The effective tax rate was 10.1%.
Operating cash flow was $25.9M (up 71% year over year), 280% of net income including minority interests. Non-cash charges added back $12.0M of depreciation and amortization and $3.6M of share-based compensation. Capital expenditures of $683K left free cash flow of $25.3M.
Questions
What was Bioventus' revenue in the second quarter 2025?
Bioventus (BVS) reported revenue of $148M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +19% from the quarter before.
Was Bioventus profitable in the second quarter 2025?
Operating profit was $18.4M (12.4% of revenue) and net earnings $7.5M.
Source: Bioventus 10-Q on SEC EDGAR.